AstraZeneca (AZN) Releases FY18 Earnings Guidance

AstraZeneca (NYSE:AZN) updated its FY18 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.46.

A number of brokerages have recently commented on AZN. ValuEngine lowered AstraZeneca from a strong-buy rating to a buy rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered AstraZeneca from a hold rating to a sell rating in a report on Monday, April 9th. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a buy rating in a report on Thursday, March 22nd. Jefferies Group upgraded AstraZeneca from a hold rating to a buy rating and upped their price target for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Leerink Swann upped their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a market perform rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $38.12.

Shares of NYSE AZN opened at $36.44 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The firm has a market capitalization of $92.45 billion, a P/E ratio of 8.51, a PEG ratio of 1.94 and a beta of 0.61. AstraZeneca has a one year low of $36.35 and a one year high of $36.55.

AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, May 18th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.20. The business had revenue of $5.18 billion during the quarter, compared to analyst estimates of $5.24 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. AstraZeneca’s revenue was down 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.99 earnings per share. equities analysts anticipate that AstraZeneca will post 1.7 EPS for the current year.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ferrellgas Partners, L.P.  Expected to Announce Earnings of $0.26 Per Share
Ferrellgas Partners, L.P. Expected to Announce Earnings of $0.26 Per Share
TPI Composites  Expected to Post Earnings of -$0.01 Per Share
TPI Composites Expected to Post Earnings of -$0.01 Per Share
PROUD Money  24 Hour Trading Volume Reaches $202.00
PROUD Money 24 Hour Trading Volume Reaches $202.00
Qvolta  Hits One Day Volume of $14,520.00
Qvolta Hits One Day Volume of $14,520.00
CDTi Advanced Materials  Trading Down 0%
CDTi Advanced Materials Trading Down 0%
Veeco Instruments Inc.  Shares Bought by Hosking Partners LLP
Veeco Instruments Inc. Shares Bought by Hosking Partners LLP


Leave a Reply

© 2006-2018 Ticker Report. Google+.